Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

INTRODUCTION: Combining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically “cold” tumors, which are typically less responsive to immunotherapy, are characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieper, Alexander A., Zangl, Luke M., Speigelman, Dan V., Feils, Arika S., Hoefges, Anna, Jagodinsky, Justin C., Felder, Mildred A., Tsarovsky, Noah W., Arthur, Ian S., Brown, Ryan J., Birstler, Jen, Le, Trang, Carlson, Peter M., Bates, Amber M., Hank, Jacquelyn A., Rakhmilevich, Alexander L., Erbe, Amy K., Sondel, Paul M., Patel, Ravi B., Morris, Zachary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634717/
https://www.ncbi.nlm.nih.gov/pubmed/34868010
http://dx.doi.org/10.3389/fimmu.2021.763888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634717/
https://www.ncbi.nlm.nih.gov/pubmed/34868010
http://dx.doi.org/10.3389/fimmu.2021.763888

Ejemplares similares